自体移植和同种异体移植在B细胞慢性淋巴细胞白血病中的作用。

Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia.

作者信息

Montserrat Emili

机构信息

Institute of Hematology and Oncology, Hospital Clinic, c/ Villarroel, 170-08036 Barcelona, Spain.

出版信息

Hematol Oncol Clin North Am. 2004 Aug;18(4):915-26, x. doi: 10.1016/j.hoc.2004.04.005.

DOI:10.1016/j.hoc.2004.04.005

PMID:15325706

Abstract

Although important progress has been made in its management, B-cell chronic lymphocytic leukemia (CLL) remains incurable with standard therapies. Hematopoietic stem-cell transplants (HSCT) are frequently being offered to individuals with CLL, the hope being that, as in other hematologic malignancies, they can prolong survival in or even cure some patients. This article analyzes which patients with CLL are appropriate candidates for HSCT, current transplant procedures, results with autologous and allogeneic HSCT, and future trends in transplantation in this form of leukemia.

摘要

尽管在B细胞慢性淋巴细胞白血病（CLL）的治疗方面已取得重要进展，但标准疗法仍无法治愈该病。造血干细胞移植（HSCT）经常应用于CLL患者，人们希望，如同在其他血液系统恶性肿瘤中一样，HSCT能够延长部分患者的生存期甚至治愈一些患者。本文分析了哪些CLL患者适合进行HSCT、当前的移植程序、自体和异基因HSCT的结果，以及这种白血病移植治疗的未来趋势。